NT-proBNP has been consistently recognized as a cardiac biomarker in CVD and is widely employed for the early detection, diagnosis, and clinical management of adverse cardiovascular events such as heart failure following a myocardial infarction. The gene discussed is NPPB; the disease is heart failure.